Analysis of molecular biology techniques for the diagnosis of human papillomavirus infection and cervical cancer prevention

Carestiato, Fernanda Nahoum; Silva, Kátia Cristina da; Balthazar, Daniela Signorelli; Silva, Licínio Esmeraldo da; Marinho, Marisa; Oliveira, Ledy H. S.; Cavalcanti, Sílvia M. B.

doi:10.1590/s0037-86822006000500002

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A strong association between HPV and cervical cancer stimulated the development of several diagnostic tests, particularly those based on molecular biology. There are currently two main approaches for molecularly detecting HPV: PCR with generic primers to amplify part of the L1 gene of the viral capsid, which is highly conserved among anogenital HPVs and the hybrid capture test (HC2), which detects the main types of HPV by forming DNA-RNA hybrids (Iftner & Villa 2003, Giovannelli et al 2004, Carestiato et al 2006. As it is more sensitive, PCR has been largely used worldwide (Gravitti et al 2000, Hubbard 2003, Kosel et al 2003.…”

mentioning

confidence: 99%

Comparison of HPV genotyping by type-specific PCR and sequencing

Carvalho

Castillo

Perone

et al. 2010

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide and there is a strong link between certain high-risk viral types and cervical carcinogenesis. Although there are several typing methods, it is still unclear which test is the best. This study compared the effectiveness of type-specific PCR (TS-PCR) and sequencing, with a focus on their clinical application. A total of 260 cervical samples from HPV-positive patients were tested for types 6, 11, 16, 18, 31, 33 and 35 using TS-PCR and sequencing. The genotype was identified in 36% of cases by TS-PCR and in 75% by sequencing. Sequencing was four times more likely to identify the viral type in positive samples than TS-PCR (p = 0.00). Despite being more effective for virus genotyping, sequencing was unable to identify viral types in multiple infections. Combining both techniques resulted in highly sensitive detection (87% of cases), showing that they are complementary methods. HPV genotyping is an important step in HPV management, helping to identify patients with a higher risk of developing cervical cancer and contributing to the development of type-specific vaccines.

show abstract

mentioning

confidence: 99%

Comparison of HPV genotyping by type-specific PCR and sequencing

Carvalho

Castillo

Perone

et al. 2010

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…However, current HPV vaccine fails to completely prevent against cervical cancer as the cervical cancer is related to more than 15 types of HPV infection [6]. Early diagnosis and treatment of high risk HPV-infection that may induce pathological changes are still keys to control cervical cancer and precancerous lesions [7,8]. Neutralizing antibodies against HPV L1 protein have shown promise in the prevention of cervical cancer [9].…”

Section: Introductionmentioning

confidence: 99%

Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein

Wang

Shang

et al. 2014

Diagn Pathol

View full text Add to dashboard Cite

BackgroundHuman papillomavirus type 16 (HPV16) infection is implicated in cervical carcinogenesis. This study aimed to characterize two new monoclonal antibodies (mAbs) against HPV L1 protein.MethodsThe immunocompetence of AE3 and AG7 mAbs for HPV L1 protein was evaluated by Western blot analysis, immunostaining, hemagglutination inhibition assay, and ELISA. The heavy chain variable region (VH) and light chain variable region (VL) of AE3 and AG7 mAbs were sequenced and analyzed.ResultsBoth mAbs specifically recognized HPV16 L1 and virus-like particles (VLPs). Both the affinity and the titer of AE3 mAb were higher than that of AG7. There were differences in sequences in the complementary determining regions (CDR) 2 and 3 of VL, as well as in the CDR1 and CDR3 of VH. The two mAbs have distinct predicted three-dimensional structures.ConclusionsWe characterized two mAbs neutralizing antibodies for HPV L1 protein, which would help develop genetic-engineered neutralizing antibodies against HPV16 for diagnostic and therapeutic purposes.

show abstract

“…Different tests for the detection of high-risk HPV have been used to assess cervical specimens 3 . The hybrid capture II (HCII) test (QIAGEN, Gaithersburg, MD, USA) is approved by the US Food and Drug Administration (FDA) and is used to validate new high-risk HPV tests for cervical screening.…”

mentioning

confidence: 99%

Hybrid capture II and PapilloCheck® tests for detection of anal high-risk human papillomavirus

Maia

Marinho

Bocca

et al. 2014

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: This study evaluated the level of concordance between hybrid capture II (HCII) and PapilloCheck ® for the detection of high-risk human papillomavirus (HPV) in anal samples. Methods: Anal cell samples collected from 42 human immunodeficiency virus (HIV)+ patients were analyzed. Results: Considering only the 13 high-risk HPV types that are detectable by both tests, HCII was positive for 52.3% of the samples, and PapilloCheck ® was positive for 52.3%. The level of concordance was 80.9% (Kappa = 0.61). Conclusions: Good concordance was observed between the tests for the detection of high-risk HPV.Keywords: Human papillomavirus. PapilloCheck ® . Hybrid capture II.Human papillomavirus (HPV) tests can be very useful for improving the sensitivity of cytology to detect anal intraepithelial neoplasia (AIN) and in post-treatment followup because of the tests' excellent negative predictive value 1,2 . Different tests for the detection of high-risk HPV have been used to assess cervical specimens 3 . The hybrid capture II (HCII) test (QIAGEN, Gaithersburg, MD, USA) is approved by the US Food and Drug Administration (FDA) and is used to validate new high-risk HPV tests for cervical screening. Two different probe cocktails are used; one comprises probes for the five low-risk genotypes, 6, 11, 42, 43 and 44, and the other contains probes for the 13 high-risk genotypes, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 4 . The test recognizes all 13 HPV types, which are classified as class I carcinogenic with respect to cervical cancer by the World Health Organization (WHO) 5 . However, this test has certain limitations, namely that it distinguishes between the high-risk and low-risk groups but does not permit the identification of specific HPV genotypes or multiple HPV infection 6 . In addition, cross-reactivity between the two probe cocktails has been observed 7 . Relative light unit (RLU)/cut-off (CO) values are considered to provide a semiquantitative estimate of viral load 4 .The PapilloCheck ® test (Greiner Bio-One, Frickenhausen, Germany) is a polymerase chain reaction (PCR)-based deoxyribonucleic acid (DNA) microarray system that allows the genotyping of 24 different HPV types (six low-risk and 18 high-risk types). The high-risk types include the 13 high-risk types detected by HCII and types 73, 82, 53, 66 and 70. The low-risk types include types 6, 11, 40, 42, 43 and 44/55 8 . The results are expressed qualitatively and semiquantitatively by signal-to-noise ratio (SNR) for 24 low-and high-risk HPV types simultaneously. The PapilloCheck ® test distinguishes HPV types and multiple HPV infection and provides the SNR value for each type 8 . The PapilloCheck ® test has been considered a reliable screening test for HPV detection and typing 9,10 . Because HCII and PapilloCheck ® are commercially available and widely used for routine diagnosis, this study evaluated their level of concordance for the detection of high-risk HPV in anal cytological samples.This study included 42 human immunodeficiency vi...

show abstract

Analysis of molecular biology techniques for the diagnosis of human papillomavirus infection and cervical cancer prevention

Cited by 4 publications

References 19 publications

Comparison of HPV genotyping by type-specific PCR and sequencing

Comparison of HPV genotyping by type-specific PCR and sequencing

Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein

Hybrid capture II and PapilloCheck® tests for detection of anal high-risk human papillomavirus

Contact Info

Product

Resources

About